BACKGROUND: We hypothesized that lymph node dissection (LND) at salvage radical prostatectomy may be associated with lower cancer-specific mortality (CSM) and we tested this hypothesis. METHODS: We relied on surveillance, epidemiology, and end results (2004-2016) to identify all salvage radical prostatectomy patients. Categorical, as well as univariate and multivariate Cox regression models tested the effect of LND (LND performed vs. not), as well as at its extent (log-transformed lymph node count) on CSM. RESULTS: Of 427 salvage radical prostatectomy patients, 120 (28.1%) underwent LND with a median lymph node count of 6 (interquartile range [IQR], 3-11). According to LND status, no significant or clinically meaningful differences were recorded in PSA at diagnosis, stage and biopsy Gleason score at diagnosis, except for age at prostate cancer diagnosis (LND performed 63 vs. 68 years LND not performed, p < .001). LND status (performed) was an independent predictor of lower CSM (hazard ratio [HR] 0.47; p = .03). Similarly, lymph node count (log transformed) also independently predicted lower CSM (HR: 0.60; p = .01). After the 7th removed lymph node, the effect of CSM became marginal. The effect of N-stage on CSM could not be tested due to insufficient number of observations. CONCLUSIONS: Salvage radical prostatectomy is rarely performed and LND at salvage radical prostatectomy is performed in a minority of patients. However, LND at salvage radical prostatectomy is associated with lower CSM. Moreover, LND extent also exerts a protective effect on CSM. These observations should be considered in salvage radical prostatectomy candidates.

Cancer Prognostics and Health Outcomes Unit Division of Urology University of Montréal Health Center Montréal Québec Canada

Department of Neurosciences Reproductive Sciences and Odontostomatology University of Naples Federico 2 Naples Italy

Department of Urology 2nd Faculty of Medicine Charles University Prag Czech Republic

Department of Urology and Division of Experimental Oncology Urological Research Institute IRCCS San Raffaele Scientific Institute Milan Italy

Department of Urology Comprehensive Cancer Center Medical University of Vienna Vienna Austria

Department of Urology Institute for Urology and Reproductive Health 1 M Sechenov 1st Moscow State Medical University Moscow Russia

Department of Urology University Hospital Frankfurt Goethe University Frankfurt Frankfurt Germany

Department of Urology University of Texas Southwestern Dallas Texas USA

Departments of Urology Weill Cornell Medical College New York New York USA

Division of Urology Department of Special Surgery Jordan University Hospital The University of Jordan Amman Jordan

Martini Klinik Prostate Cancer Center University Hospital Hamburg Eppendorf Hamburg Germany

Prostate. 2021 Aug;81(11):795. doi: 10.1002/pros.24149. PubMed

Prostate. 2021 Aug;81(11):794. doi: 10.1002/pros.24147. PubMed

Zobrazit více v PubMed

Mottet N, Cornford P, Van den Bergh RCN, et al. EAU - EANM - ESTRO - ESUR - SIOG. guidelines on prostate cancer. Eur Urol. 2020.

Mohler JL, Antonarakis ES, Armstrong AJ, et al. Prostate cancer, version 1.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020.

Mandel P, Steuber T, Ahyai S, et al. Salvage radical prostatectomy for recurrent prostate cancer: verification of European Association of Urology guideline criteria. BJU Int. 2016;117(1):55-61.

Heidenreich A, Richter S, Thüer D, Pfister D. Prognostic parameters, complications, and oncologic and functional outcome of salvage radical prostatectomy for locally recurrent prostate cancer after 21st-century radiotherapy. Eur Urol. 2010;57(3):437-443.

Chade DC, Shariat SF, Cronin AM, et al. Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration. Eur Urol. 2011;60(2):205-210.

Sanderson KM, Penson DF, Cai J, et al. Salvage radical prostatectomy: quality of life outcomes and long-term oncological control of radiorecurrent prostate cancer. J Urol. 2006;176(5):2025-2031.

Pokala N, Huynh DL, Henderson AA, Johans C. Survival outcomes in men undergoing radical prostatectomy after primary radiation treatment for adenocarcinoma of the prostate. Clin Genitourin Cancer. 2016;14(3):218-225.

About the SEER Program [Internet]. SEER. [cited 2020 August 20]. Available from: https://seer.cancer.gov/about/overview.html

RCT. R: A language and environment for statistical computing. https://wwwr-projectorg2017

Preisser F, Mazzone E, Knipper S, et al. Rates of positive surgical margins and their effect on cancer-specific mortality at radical prostatectomy for patients with clinically localized prostate cancer. Clin Genitourin Cancer. 2019;17(1):e130-e139.

Heidenreich A, Ohlmann C, Ozgür E, Engelmann U. Functional and oncological outcome of salvage prostatectomy of locally recurrent prostate cancer following radiation therapy. Urologe A. 2006;45(4):474-481.

Gheiler EL, Tefilli MV, Tiguert R, et al. Predictors for maximal outcome in patients undergoing salvage surgery for radio-recurrent prostate cancer. Urology. 1998;51(5):789-795.

Stephenson AJ, Scardino PT, Bianco FJ, DiBlasio CJ, Fearn PA, Eastham JA. Morbidity and functional outcomes of salvage radical prostatectomy for locally recurrent prostate cancer after radiation therapy. J Urol. 2004;172(6 Pt 1):2239-2243.

Ward JF, Sebo TJ, Blute ML, Zincke H. Salvage surgery for radiorecurrent prostate cancer: contemporary outcomes. J Urol. 2005;173(4):1156-1160.

Agarwal PK, Sadetsky N, Konety BR, Resnick MI, Carroll PR. Cancer of the Prostate Strategic Urological Research Endeavor (CaPSURE). Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes. Cancer. 2008;112(2):307-314.

Doublet JD, Gattegno B, Thibault P. Laparoscopic pelvic lymph node dissection for staging of prostatic cancer. Eur Urol. 1994;25(3):194-198.

Preisser F, van den Bergh RCN, Gandaglia G, et al. Effect of extended pelvic lymph node dissection on oncologic outcomes in patients with d′amico intermediate and high risk prostate cancer treated with radical prostatectomy: a multi-institutional study. J Urol. 2020;203(2):338-343.

Gandaglia G, De Lorenzis E, Novara G, et al. Robot-assisted radical prostatectomy and extended pelvic lymph node dissection in patients with locally-advanced prostate cancer. Eur Urol. 2017;71(2):249-256.

Hoffman RM, Meisner ALW, Arap W, et al. Trends in United States prostate cancer incidence rates by age and stage, 1995-2012. Cancer Epidemiol Biomarkers Prev. 2016;25(2):259-263.

Abdollah F, Gandaglia G, Suardi N, et al. More extensive pelvic lymph node dissection improves survival in patients with node-positive prostate cancer. Eur Urol. 2015;67(2):212-219.

Moschini M, Fossati N, Abdollah F, et al. Determinants of long-term survival of patients with locally advanced prostate cancer: the role of extensive pelvic lymph node dissection. Prostate Cancer Prostatic Dis. 2016;19(1):63-67.

Heidenreich A, Varga Z, Von Knobloch R. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J Urol. 2002;167(4):1681-1686.

Clark T, Parekh DJ, Cookson MS, et al. Randomized prospective evaluation of extended versus limited lymph node dissection in patients with clinically localized prostate cancer. J Urol. 2003;169(1):145-147.

Molinié V, Mahjoub WK, Balaton A. Histological modifications observed in prostate after preserving treatments for prostate cancer and their impact on Gleason score interpretation. Ann Pathol. 2008;28(5):363-373.

Bazinet M, Zheng W, Bégin LR, Aprikian AG, Karakiewicz PI, Elhilali MM. Morphologic changes induced by neoadjuvant androgen ablation may result in underdetection of positive surgical margins and capsular involvement by prostatic adenocarcinoma. Urology. 1997;49(5):721-725.

Preisser F, Bandini M, Marchioni M, et al. Extent of lymph node dissection improves survival in prostate cancer patients treated with radical prostatectomy without lymph node invasion. Prostate. 2018;78(6):469-475.

Soni PD, Hartman HE, Dess RT, et al. Comparison of population-based observational studies with randomized trials in oncology. J Clin Oncol Off J Am Soc Clin Oncol. 2019;37(14):1209-1216.

Impact of persistent PSA after salvage radical prostatectomy: a multicenter study

Oncologic Outcomes of Lymph Node Dissection at Salvage Radical Prostatectomy

The effect of race/ethnicity on cancer-specific mortality after salvage radical prostatectomy

The role of lymph node dissection in salvage radical prostatectomy for patients with radiation recurrent prostate cancer